羚锐制药:公司点评报告:利润增长超预期,业绩稳步增长可期
Lingrui Pharma(600285) 中原证券·2024-08-15 08:30
中药生产 分析师:李琳琳 登记编码:S0730511010010 lill@ccnew.com 021-50586983 利润增长超预期,业绩稳步增长可期 ——羚锐制药(600285)公司点评报告 | --- | --- | --- | --- | |-----------------------------------------|----------------------------------------------------------------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...